Dec 2 (Reuters) - Appili Therapeutics Inc APLI.TO :
* FIRST PATIENT DOSED IN APPILI THERAPEUTICS' PHASE 3 CLINICAL TRIAL OF AVIGAN® TABLETS (FAVIPIRAVIR) FOR THE TREATMENT OF COVID-19 IN THE UNITED STATES
* APPILI THERAPEUTICS INC - EXPECTS TO REPORT EARLY DATA FROM PRESECO STUDY IN FIRST HALF OF 2021